Aclaris Therapeutics (ACRS) Downgraded by ValuEngine to Sell

ValuEngine cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research report report published on Wednesday, May 1st, ValuEngine reports.

ACRS has been the subject of a number of other reports. Zacks Investment Research lowered Aclaris Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 23rd. Cantor Fitzgerald reaffirmed a buy rating and issued a $50.00 price objective on shares of Aclaris Therapeutics in a research note on Friday, March 15th. Finally, BidaskClub raised Aclaris Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $26.19.

ACRS traded down $0.12 during midday trading on Wednesday, reaching $5.64. The company had a trading volume of 299,359 shares, compared to its average volume of 523,261. The company has a quick ratio of 4.30, a current ratio of 4.33 and a debt-to-equity ratio of 0.16. The stock has a market cap of $237.72 million, a price-to-earnings ratio of -1.40 and a beta of 1.24. Aclaris Therapeutics has a 1 year low of $5.04 and a 1 year high of $21.97.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.05). Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%. The business had revenue of $5.04 million for the quarter, compared to analysts’ expectations of $5.13 million. On average, equities analysts anticipate that Aclaris Therapeutics will post -2.97 earnings per share for the current fiscal year.

In other Aclaris Therapeutics news, major shareholder James E. Flynn sold 614,710 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $6.13, for a total transaction of $3,768,172.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 14.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlueMountain Capital Management LLC increased its holdings in Aclaris Therapeutics by 129.6% during the 1st quarter. BlueMountain Capital Management LLC now owns 55,784 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 31,493 shares during the period. Morgan Stanley increased its holdings in shares of Aclaris Therapeutics by 23.8% in the 1st quarter. Morgan Stanley now owns 206,755 shares of the biotechnology company’s stock valued at $1,238,000 after acquiring an additional 39,712 shares during the period. Man Group plc increased its holdings in shares of Aclaris Therapeutics by 77.9% in the 1st quarter. Man Group plc now owns 1,185,528 shares of the biotechnology company’s stock valued at $7,101,000 after acquiring an additional 519,098 shares during the period. Oxford Asset Management LLP increased its holdings in shares of Aclaris Therapeutics by 52.1% in the 1st quarter. Oxford Asset Management LLP now owns 35,230 shares of the biotechnology company’s stock valued at $211,000 after acquiring an additional 12,072 shares during the period. Finally, Broadfin Capital LLC increased its holdings in shares of Aclaris Therapeutics by 8.2% in the 1st quarter. Broadfin Capital LLC now owns 2,030,925 shares of the biotechnology company’s stock valued at $12,165,000 after acquiring an additional 153,423 shares during the period. Institutional investors own 95.04% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Further Reading: How to Use the New Google Finance Tool

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.